This Article Full Text Full Text (PDF) All Versions of this Article: 40/5/e292    most recent STROKEAHA.108.544544v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Higgins, P. Articles by Lees, K. R. Search for Related Content PubMed PubMed Citation Articles by Higgins, P. Articles by Lees, K. R. Related Collections Other Stroke Treatment - Medical

(Stroke. 2009;40:e292.)
© 2009 American Heart Association, Inc.

Advances in Stroke 2008

Advances in Emerging Therapies

From the Department of Medicine & Therapeutics, Faculty of Medicine, University of Glasgow, Glasgow, UK.

Correspondence to Peter Higgins, BSc(Hons), MBChB, Western Infirmary, Dumbarton Road, Glasgow G11 6NT, UK. E-mail peter-higgins@doctors.org.uk

Key Words: thrombolysis • advances • emerging therapies

An extract of the first 250 words of the full text is provided, because this article has no abstract.

	Introduction

 
Historically, stroke has proven to be a condition poorly amenable to treatment, and the last year delivered its share of neutral results in this regard. However, other studies suggested promising areas for pursuit while a couple grabbed the headlines and will modify clinical practice.

	Thrombolysis

 
We can justifiably emphasize the findings of the third European Cooperative Acute Stroke Study (ECASS-3), which has recently confirmed the use of thrombolytic therapy up to 4.5 hours after onset of ischemic stroke.¹ The reality is that alteplase was already a safe and highly effective treatment before the results of ECASS-3 became known. However, a minority allowed their uncertainty over safety and doubts raised by individually neutral trials to restrict implementation of this potent therapy. The latest result broadens the range of patients who may benefit but it has implications beyond these narrow confines. Even after accounting for the expected low rate of symptomatic bleeding—just 2% excess over placebo—alteplase treatment delivered a 10% absolute increase in proportion of patients attaining excellent outcome, indicating 3 valuable lessons. First, any residual doubts over the safety or efficacy of intravenous alteplase early after stroke have been annulled. Second, the challenging time window for treatment can be relaxed, provided this is not at the expense of slower reaction by services. Third, there is evidently scope for further extension of treatment and enhancement of alteplase’s action that begs continued research. We need to test extended patient selection, perhaps via imaging strategies. We must also assess whether we can enhance the extent . . . [Full Text of this Article]